XBiotech Inc. (XBIT) 10-Year Financial Performance & Capital Metrics

XBIT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.Show more

Revenue $0
EBITDA -$41M -13.9%
Net Income -$39M -56.9%
EPS (Diluted) -1.26 -55.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.21% -79.6%
ROIC -164.77% -198.5%
Debt/Equity 0.06
Interest Coverage -52.63

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.5%

ROCE

10Y Avg-27.97%

5Y Avg-12.4%

3Y Avg-16.88%

Latest-21%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	44M	18.39M	4.01M	0	0
Revenue Growth %	-	-	-	-	-	-	-0.58%	-0.78%	-1%	-
Cost of Goods Sold+	699K	698K	1.48M	2.43M	2.36M	34.55M	5.82M	651K	0	0
COGS % of Revenue	-	-	-	-	-	0.79%	0.32%	0.16%	-	-
Gross Profit+	-699K	-698K	-1.48M	-2.43M	-2.36M	9.45M	12.57M	3.36M	0	0
Gross Margin %	-	-	-	-	-	0.21%	0.68%	0.84%	-	-
Gross Profit Growth %	-	0%	-1.13%	-0.64%	0.03%	5%	0.33%	-0.73%	-1%	-
Operating Expenses+	37.51M	52.76M	34.06M	20.99M	28.87M	27.73M	37.66M	37.85M	37.51M	42.47M
OpEx % of Revenue	-	-	-	-	-	0.63%	2.05%	9.44%	-	-
Selling, General & Admin	6.2M	10.28M	7.63M	5.27M	4.78M	18.2M	9.39M	6.3M	4.66M	4.71M
SG&A % of Revenue	-	-	-	-	-	0.41%	0.51%	1.57%	-	-
Research & Development	31.31M	42.49M	26.42M	15.72M	24.09M	9.53M	28.27M	31.54M	32.85M	37.76M
R&D % of Revenue	-	-	-	-	-	0.22%	1.54%	7.87%	-	-
Other Operating Expenses	21K	0	0	4K	0	0	0	0	0	0
Operating Income+	-37.51M	-52.76M	-34.06M	-20.99M	-31.23M	-18.28M	-25.08M	-34.49M	-37.51M	-42.47M
Operating Margin %	-	-	-	-	-	-0.42%	-1.36%	-8.6%	-	-
Operating Income Growth %	-0.72%	-0.41%	0.35%	0.38%	-0.49%	0.41%	-0.37%	-0.38%	-0.09%	-0.13%
EBITDA+	-36.81M	-52.06M	-32.58M	-18.56M	-28.87M	-16.04M	-22.43M	-31.88M	-35.77M	-40.73M
EBITDA Margin %	-	-	-	-	-	-0.36%	-1.22%	-7.95%	-	-
EBITDA Growth %	-0.74%	-0.41%	0.37%	0.43%	-0.56%	0.44%	-0.4%	-0.42%	-0.12%	-0.14%
D&A (Non-Cash Add-back)	699K	698K	1.48M	2.43M	2.36M	2.24M	2.65M	2.61M	1.74M	1.75M
EBIT	-37.51M	-52.76M	-34.06M	-21.14M	718.45M	-18.28M	-25.08M	-34.49M	-24.31M	-37.76M
Net Interest Income+	0	0	0	0	564K	2.46M	467K	3.82M	10.42M	9.01M
Interest Income	0	49K	354K	400K	564K	2.46M	467K	3.82M	10.42M	9.81M
Interest Expense	0	0	0	0	0	0	0	0	0	807K
Other Income/Expense	27K	2K	909K	-144K	749.69M	5.45M	-376K	902K	13.2M	3.91M
Pretax Income+	-37.48M	-52.76M	-33.15M	-21.14M	718.45M	-12.83M	-25.46M	-33.59M	-24.31M	-38.56M
Pretax Margin %	-	-	-	-	-	-0.29%	-1.38%	-8.38%	-	-
Income Tax+	-6K	-2K	0	-144K	49.82M	-1.61M	-8.04M	-688K	244K	-32K
Effective Tax Rate %	1%	1%	1%	1%	0.93%	0.87%	0.68%	0.98%	1.01%	1%
Net Income+	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Net Margin %	-	-	-	-	-	-0.26%	-0.95%	-8.2%	-	-
Net Income Growth %	-0.73%	-0.41%	0.37%	0.36%	32.63%	-1.02%	-0.55%	-0.89%	0.25%	-0.57%
Net Income (Continuing)	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.22	-1.63	-0.95	-0.59	14.44	-0.36	-0.58	-1.08	-0.81	-1.26
EPS Growth %	-0.79%	-0.34%	0.42%	0.38%	25.47%	-1.02%	-0.61%	-0.86%	0.25%	-0.56%
EPS (Basic)	-1.22	-1.63	-0.95	-0.59	17.17	-0.36	-0.58	-1.08	-0.81	-1.26
Diluted Shares Outstanding	30.8M	32.4M	34.88M	35.8M	46.32M	30.82M	30.04M	30.44M	30.44M	30.46M
Basic Shares Outstanding	30.8M	32.4M	34.88M	35.8M	38.95M	30.82M	30.04M	30.44M	30.32M	30.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	93.04M	36.93M	33.33M	17.02M	716.26M	325.88M	246.87M	219.84M	201.72M	174.57M
Cash & Short-Term Investments	91.05M	34.32M	31.77M	15.82M	714.59M	237.37M	236.98M	217.48M	200.02M	172.68M
Cash Only	91.05M	34.32M	31.77M	15.82M	714.59M	237.37M	236.98M	157.31M	200.02M	172.68M
Short-Term Investments	0	0	0	0	0	0	0	60.17M	0	0
Accounts Receivable	0	0	0	0	0	4.11M	8.95M	1.76M	935K	858K
Days Sales Outstanding	-	-	-	-	-	34.12	177.66	160.56	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	2.61M	1.56M	1.19M	1.67M	83.81M	0	601K	760K	1.03M
Total Non-Current Assets+	16.32M	30.12M	29.64M	27.33M	100.61M	27.87M	28.31M	26.26M	24.9M	24.53M
Property, Plant & Equipment	16.32M	30.12M	29.64M	27.33M	25.17M	27.34M	28.31M	26.26M	24.9M	24.53M
Fixed Asset Turnover	-	-	-	-	-	1.61x	0.65x	0.15x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	75M	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	75M	0	-1.09M	-1.66M	0	0
Total Assets+	109.36M	67.05M	62.97M	44.34M	816.88M	353.74M	275.18M	246.1M	226.62M	199.09M
Asset Turnover	-	-	-	-	-	0.12x	0.07x	0.02x	-	-
Asset Growth %	0.76%	-0.39%	-0.06%	-0.3%	17.42%	-0.57%	-0.22%	-0.11%	-0.08%	-0.12%
Total Current Liabilities+	6.29M	7.96M	2.79M	2.94M	60.19M	3.98M	3.45M	4.07M	6.1M	15.11M
Accounts Payable	4.83M	4.43M	1.73M	1.65M	2.15M	2.49M	2.07M	2.41M	2.52M	2.22M
Days Payables Outstanding	2.52K	2.32K	425.51	247.98	332.23	26.32	129.76	1.35K	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	10.25M
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	0	0
Other Current Liabilities	421K	521K	0	0	53.2M	1.05M	904K	1.17M	562K	611K
Current Ratio	14.79x	4.64x	11.94x	5.78x	11.90x	81.80x	71.49x	54.07x	33.07x	11.56x
Quick Ratio	14.79x	4.64x	11.94x	5.78x	11.90x	81.80x	71.49x	54.07x	33.07x	11.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17K	23K	18K	3K	1.06M	1.12M	2.34M	1.64M	1.67M	1.72M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	446K	0	873K	59K	0	0
Other Non-Current Liabilities	17K	23K	18K	3K	1.06M	1.12M	1.47M	1.58M	1.67M	1.72M
Total Liabilities	6.31M	7.99M	2.81M	2.95M	61.25M	5.11M	5.79M	5.7M	7.77M	16.82M
Total Debt+	0	0	0	0	0	0	0	0	0	10.25M
Net Debt	-91.05M	-34.32M	-31.77M	-15.82M	-714.59M	-237.37M	-236.98M	-157.31M	-200.02M	-162.43M
Debt / Equity	-	-	-	-	-	-	-	-	-	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-52.63x
Total Equity+	103.05M	59.06M	60.16M	41.4M	755.63M	348.64M	269.38M	240.4M	218.85M	182.27M
Equity Growth %	0.75%	-0.43%	0.02%	-0.31%	17.25%	-0.54%	-0.23%	-0.11%	-0.09%	-0.17%
Book Value per Share	3.35	1.82	1.73	1.16	16.31	11.31	8.97	7.90	7.19	5.98
Total Shareholders' Equity	103.05M	59.06M	60.16M	41.4M	755.63M	348.64M	269.38M	240.4M	218.85M	182.27M
Common Stock	233.9M	242.42M	277.49M	279.35M	324.81M	249.81M	262.26M	267.32M	271.15M	273.11M
Retained Earnings	-130.65M	-183.41M	-216.56M	-237.7M	430.93M	97.57M	5.15M	-27.75M	-52.31M	-90.84M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-201K	57K	-768K	-255K	-106K	1.27M	1.97M	826K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.31M	-46.02M	-33.65M	-16.54M	-18.27M	-65.15M	69.44M	-14.82M	-18.73M	-30.96M
Operating CF Margin %	-	-	-	-	-	-1.48%	3.78%	-3.7%	-	-
Operating CF Growth %	-1.85%	-0.38%	0.27%	0.51%	-0.1%	-2.57%	2.07%	-1.21%	-0.26%	-0.65%
Net Income	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Depreciation & Amortization	699K	698K	1.48M	2.43M	2.36M	2.24M	2.65M	2.61M	1.74M	1.75M
Stock-Based Compensation	4.41M	5.57M	1.75M	1.66M	3.36M	12.58M	4.46M	5.06M	0	1.75M
Deferred Taxes	0	0	0	0	-444K	-90K	0	0	0	0
Other Non-Cash Items	-157K	6.97M	401K	6.53M	-674.56M	90K	0	2.8M	1.37M	5.53M
Working Capital Changes	-774K	475K	-4.13M	508K	-17.62M	-68.75M	79.75M	7.6M	2.72M	-1.46M
Change in Receivables	0	0	0	0	0	-10.69M	1.73M	7.34M	829K	77K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	840K	-981K	-2.7M	-78K	496K	-334K	-514K	357K	91K	-364K
Cash from Investing+	-10.39M	-13.91M	-1.41M	-122K	674.8M	-3.73M	-3.52M	-63.89M	61.5M	-1.3M
Capital Expenditures	-10.39M	-13.91M	-1.41M	-122K	-204K	-3.73M	-3.52M	-585K	-362K	-1.3M
CapEx % of Revenue	-	-	-	-	-	0.08%	0.19%	0.15%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-8.07M	-9.17M	0	0	0	0	0	0	61.86M	0
Cash from Financing+	77.47M	2.94M	33.32M	201K	42.1M	-409.72M	-67.01M	0	-9K	10.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-75M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.76M	1.14M	703K	201K	4.03M	10.28M	8M	0	-14K	200K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-43.7M	-59.93M	-35.05M	-16.66M	-18.47M	-68.88M	65.92M	-15.41M	-19.09M	-32.27M
FCF Margin %	-	-	-	-	-	-1.57%	3.58%	-3.84%	-	-
FCF Growth %	-2.34%	-0.37%	0.42%	0.52%	-0.11%	-2.73%	1.96%	-1.23%	-0.24%	-0.69%
FCF per Share	-1.42	-1.85	-1.01	-0.47	-0.40	-2.23	2.19	-0.51	-0.63	-1.06
FCF Conversion (FCF/Net Income)	0.89x	0.87x	1.02x	0.78x	-0.03x	5.81x	-3.99x	0.45x	0.76x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	400K
Taxes Paid	0	0	0	0	0	54.09M	0	0	0	85K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.25%	-65.09%	-55.61%	-41.63%	167.78%	-2.03%	-5.64%	-12.91%	-10.69%	-19.21%
Return on Invested Capital (ROIC)	-410.69%	-215.42%	-96.15%	-58.35%	-70.33%	-18%	-26.19%	-44.79%	-55.21%	-164.77%
Gross Margin	-	-	-	-	-	21.48%	68.36%	83.77%	-	-
Net Margin	-	-	-	-	-	-25.5%	-94.67%	-820.45%	-	-
Debt / Equity	-	-	-	-	-	-	-	-	-	0.06x
Interest Coverage	-	-	-	-	-	-	-	-	-	-52.63x
FCF Conversion	0.89x	0.87x	1.02x	0.78x	-0.03x	5.81x	-3.99x	0.45x	0.76x	0.80x
Revenue Growth	-	-	-	-	-	-	-58.19%	-78.2%	-100%	-

Revenue by Segment

	2020	2021	2022
Manufacturing Revenue	18M	18M	4.01M
Manufacturing Revenue Growth	-	0.00%	-77.72%
Clinical Trial Service Revenue	25.98M	394K	-
Clinical Trial Service Revenue Growth	-	-98.48%	-
Product and Service, Other	22K	-	-
Product and Service, Other Growth	-	-	-

Frequently Asked Questions

Growth & Financials

XBiotech Inc. (XBIT) grew revenue by 0.0% over the past year. Growth has been modest.

XBiotech Inc. (XBIT) reported a net loss of $29.2M for fiscal year 2024.

Dividend & Returns

XBiotech Inc. (XBIT) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

XBiotech Inc. (XBIT) had negative free cash flow of $23.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

XBiotech Inc. (XBIT) 10-Year Financial Performance & Capital Metrics

XBIT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$41M -13.9%
Net Income -$39M -56.9%
EPS (Diluted) -1.26 -55.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -19.21% -79.6%
ROIC -164.77% -198.5%
Debt/Equity 0.06
Interest Coverage -52.63

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.72%

EPS CAGR

10Y-

5Y-

3Y-

TTM10.5%

ROCE

10Y Avg-27.97%

5Y Avg-12.4%

3Y Avg-16.88%

Latest-21%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	44M	18.39M	4.01M	0	0
Revenue Growth %	-	-	-	-	-	-	-0.58%	-0.78%	-1%	-
Cost of Goods Sold+	699K	698K	1.48M	2.43M	2.36M	34.55M	5.82M	651K	0	0
COGS % of Revenue	-	-	-	-	-	0.79%	0.32%	0.16%	-	-
Gross Profit+	-699K	-698K	-1.48M	-2.43M	-2.36M	9.45M	12.57M	3.36M	0	0
Gross Margin %	-	-	-	-	-	0.21%	0.68%	0.84%	-	-
Gross Profit Growth %	-	0%	-1.13%	-0.64%	0.03%	5%	0.33%	-0.73%	-1%	-
Operating Expenses+	37.51M	52.76M	34.06M	20.99M	28.87M	27.73M	37.66M	37.85M	37.51M	42.47M
OpEx % of Revenue	-	-	-	-	-	0.63%	2.05%	9.44%	-	-
Selling, General & Admin	6.2M	10.28M	7.63M	5.27M	4.78M	18.2M	9.39M	6.3M	4.66M	4.71M
SG&A % of Revenue	-	-	-	-	-	0.41%	0.51%	1.57%	-	-
Research & Development	31.31M	42.49M	26.42M	15.72M	24.09M	9.53M	28.27M	31.54M	32.85M	37.76M
R&D % of Revenue	-	-	-	-	-	0.22%	1.54%	7.87%	-	-
Other Operating Expenses	21K	0	0	4K	0	0	0	0	0	0
Operating Income+	-37.51M	-52.76M	-34.06M	-20.99M	-31.23M	-18.28M	-25.08M	-34.49M	-37.51M	-42.47M
Operating Margin %	-	-	-	-	-	-0.42%	-1.36%	-8.6%	-	-
Operating Income Growth %	-0.72%	-0.41%	0.35%	0.38%	-0.49%	0.41%	-0.37%	-0.38%	-0.09%	-0.13%
EBITDA+	-36.81M	-52.06M	-32.58M	-18.56M	-28.87M	-16.04M	-22.43M	-31.88M	-35.77M	-40.73M
EBITDA Margin %	-	-	-	-	-	-0.36%	-1.22%	-7.95%	-	-
EBITDA Growth %	-0.74%	-0.41%	0.37%	0.43%	-0.56%	0.44%	-0.4%	-0.42%	-0.12%	-0.14%
D&A (Non-Cash Add-back)	699K	698K	1.48M	2.43M	2.36M	2.24M	2.65M	2.61M	1.74M	1.75M
EBIT	-37.51M	-52.76M	-34.06M	-21.14M	718.45M	-18.28M	-25.08M	-34.49M	-24.31M	-37.76M
Net Interest Income+	0	0	0	0	564K	2.46M	467K	3.82M	10.42M	9.01M
Interest Income	0	49K	354K	400K	564K	2.46M	467K	3.82M	10.42M	9.81M
Interest Expense	0	0	0	0	0	0	0	0	0	807K
Other Income/Expense	27K	2K	909K	-144K	749.69M	5.45M	-376K	902K	13.2M	3.91M
Pretax Income+	-37.48M	-52.76M	-33.15M	-21.14M	718.45M	-12.83M	-25.46M	-33.59M	-24.31M	-38.56M
Pretax Margin %	-	-	-	-	-	-0.29%	-1.38%	-8.38%	-	-
Income Tax+	-6K	-2K	0	-144K	49.82M	-1.61M	-8.04M	-688K	244K	-32K
Effective Tax Rate %	1%	1%	1%	1%	0.93%	0.87%	0.68%	0.98%	1.01%	1%
Net Income+	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Net Margin %	-	-	-	-	-	-0.26%	-0.95%	-8.2%	-	-
Net Income Growth %	-0.73%	-0.41%	0.37%	0.36%	32.63%	-1.02%	-0.55%	-0.89%	0.25%	-0.57%
Net Income (Continuing)	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.22	-1.63	-0.95	-0.59	14.44	-0.36	-0.58	-1.08	-0.81	-1.26
EPS Growth %	-0.79%	-0.34%	0.42%	0.38%	25.47%	-1.02%	-0.61%	-0.86%	0.25%	-0.56%
EPS (Basic)	-1.22	-1.63	-0.95	-0.59	17.17	-0.36	-0.58	-1.08	-0.81	-1.26
Diluted Shares Outstanding	30.8M	32.4M	34.88M	35.8M	46.32M	30.82M	30.04M	30.44M	30.44M	30.46M
Basic Shares Outstanding	30.8M	32.4M	34.88M	35.8M	38.95M	30.82M	30.04M	30.44M	30.32M	30.46M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	93.04M	36.93M	33.33M	17.02M	716.26M	325.88M	246.87M	219.84M	201.72M	174.57M
Cash & Short-Term Investments	91.05M	34.32M	31.77M	15.82M	714.59M	237.37M	236.98M	217.48M	200.02M	172.68M
Cash Only	91.05M	34.32M	31.77M	15.82M	714.59M	237.37M	236.98M	157.31M	200.02M	172.68M
Short-Term Investments	0	0	0	0	0	0	0	60.17M	0	0
Accounts Receivable	0	0	0	0	0	4.11M	8.95M	1.76M	935K	858K
Days Sales Outstanding	-	-	-	-	-	34.12	177.66	160.56	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	2.61M	1.56M	1.19M	1.67M	83.81M	0	601K	760K	1.03M
Total Non-Current Assets+	16.32M	30.12M	29.64M	27.33M	100.61M	27.87M	28.31M	26.26M	24.9M	24.53M
Property, Plant & Equipment	16.32M	30.12M	29.64M	27.33M	25.17M	27.34M	28.31M	26.26M	24.9M	24.53M
Fixed Asset Turnover	-	-	-	-	-	1.61x	0.65x	0.15x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	75M	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	75M	0	-1.09M	-1.66M	0	0
Total Assets+	109.36M	67.05M	62.97M	44.34M	816.88M	353.74M	275.18M	246.1M	226.62M	199.09M
Asset Turnover	-	-	-	-	-	0.12x	0.07x	0.02x	-	-
Asset Growth %	0.76%	-0.39%	-0.06%	-0.3%	17.42%	-0.57%	-0.22%	-0.11%	-0.08%	-0.12%
Total Current Liabilities+	6.29M	7.96M	2.79M	2.94M	60.19M	3.98M	3.45M	4.07M	6.1M	15.11M
Accounts Payable	4.83M	4.43M	1.73M	1.65M	2.15M	2.49M	2.07M	2.41M	2.52M	2.22M
Days Payables Outstanding	2.52K	2.32K	425.51	247.98	332.23	26.32	129.76	1.35K	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	10.25M
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	0	0
Other Current Liabilities	421K	521K	0	0	53.2M	1.05M	904K	1.17M	562K	611K
Current Ratio	14.79x	4.64x	11.94x	5.78x	11.90x	81.80x	71.49x	54.07x	33.07x	11.56x
Quick Ratio	14.79x	4.64x	11.94x	5.78x	11.90x	81.80x	71.49x	54.07x	33.07x	11.56x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17K	23K	18K	3K	1.06M	1.12M	2.34M	1.64M	1.67M	1.72M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	446K	0	873K	59K	0	0
Other Non-Current Liabilities	17K	23K	18K	3K	1.06M	1.12M	1.47M	1.58M	1.67M	1.72M
Total Liabilities	6.31M	7.99M	2.81M	2.95M	61.25M	5.11M	5.79M	5.7M	7.77M	16.82M
Total Debt+	0	0	0	0	0	0	0	0	0	10.25M
Net Debt	-91.05M	-34.32M	-31.77M	-15.82M	-714.59M	-237.37M	-236.98M	-157.31M	-200.02M	-162.43M
Debt / Equity	-	-	-	-	-	-	-	-	-	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-52.63x
Total Equity+	103.05M	59.06M	60.16M	41.4M	755.63M	348.64M	269.38M	240.4M	218.85M	182.27M
Equity Growth %	0.75%	-0.43%	0.02%	-0.31%	17.25%	-0.54%	-0.23%	-0.11%	-0.09%	-0.17%
Book Value per Share	3.35	1.82	1.73	1.16	16.31	11.31	8.97	7.90	7.19	5.98
Total Shareholders' Equity	103.05M	59.06M	60.16M	41.4M	755.63M	348.64M	269.38M	240.4M	218.85M	182.27M
Common Stock	233.9M	242.42M	277.49M	279.35M	324.81M	249.81M	262.26M	267.32M	271.15M	273.11M
Retained Earnings	-130.65M	-183.41M	-216.56M	-237.7M	430.93M	97.57M	5.15M	-27.75M	-52.31M	-90.84M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-201K	57K	-768K	-255K	-106K	1.27M	1.97M	826K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-33.31M	-46.02M	-33.65M	-16.54M	-18.27M	-65.15M	69.44M	-14.82M	-18.73M	-30.96M
Operating CF Margin %	-	-	-	-	-	-1.48%	3.78%	-3.7%	-	-
Operating CF Growth %	-1.85%	-0.38%	0.27%	0.51%	-0.1%	-2.57%	2.07%	-1.21%	-0.26%	-0.65%
Net Income	-37.48M	-52.76M	-33.15M	-21.14M	668.63M	-11.22M	-17.41M	-32.9M	-24.56M	-38.53M
Depreciation & Amortization	699K	698K	1.48M	2.43M	2.36M	2.24M	2.65M	2.61M	1.74M	1.75M
Stock-Based Compensation	4.41M	5.57M	1.75M	1.66M	3.36M	12.58M	4.46M	5.06M	0	1.75M
Deferred Taxes	0	0	0	0	-444K	-90K	0	0	0	0
Other Non-Cash Items	-157K	6.97M	401K	6.53M	-674.56M	90K	0	2.8M	1.37M	5.53M
Working Capital Changes	-774K	475K	-4.13M	508K	-17.62M	-68.75M	79.75M	7.6M	2.72M	-1.46M
Change in Receivables	0	0	0	0	0	-10.69M	1.73M	7.34M	829K	77K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	840K	-981K	-2.7M	-78K	496K	-334K	-514K	357K	91K	-364K
Cash from Investing+	-10.39M	-13.91M	-1.41M	-122K	674.8M	-3.73M	-3.52M	-63.89M	61.5M	-1.3M
Capital Expenditures	-10.39M	-13.91M	-1.41M	-122K	-204K	-3.73M	-3.52M	-585K	-362K	-1.3M
CapEx % of Revenue	-	-	-	-	-	0.08%	0.19%	0.15%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-8.07M	-9.17M	0	0	0	0	0	0	61.86M	0
Cash from Financing+	77.47M	2.94M	33.32M	201K	42.1M	-409.72M	-67.01M	0	-9K	10.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	-75M	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.76M	1.14M	703K	201K	4.03M	10.28M	8M	0	-14K	200K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-43.7M	-59.93M	-35.05M	-16.66M	-18.47M	-68.88M	65.92M	-15.41M	-19.09M	-32.27M
FCF Margin %	-	-	-	-	-	-1.57%	3.58%	-3.84%	-	-
FCF Growth %	-2.34%	-0.37%	0.42%	0.52%	-0.11%	-2.73%	1.96%	-1.23%	-0.24%	-0.69%
FCF per Share	-1.42	-1.85	-1.01	-0.47	-0.40	-2.23	2.19	-0.51	-0.63	-1.06
FCF Conversion (FCF/Net Income)	0.89x	0.87x	1.02x	0.78x	-0.03x	5.81x	-3.99x	0.45x	0.76x	0.80x
Interest Paid	0	0	0	0	0	0	0	0	0	400K
Taxes Paid	0	0	0	0	0	54.09M	0	0	0	85K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.25%	-65.09%	-55.61%	-41.63%	167.78%	-2.03%	-5.64%	-12.91%	-10.69%	-19.21%
Return on Invested Capital (ROIC)	-410.69%	-215.42%	-96.15%	-58.35%	-70.33%	-18%	-26.19%	-44.79%	-55.21%	-164.77%
Gross Margin	-	-	-	-	-	21.48%	68.36%	83.77%	-	-
Net Margin	-	-	-	-	-	-25.5%	-94.67%	-820.45%	-	-
Debt / Equity	-	-	-	-	-	-	-	-	-	0.06x
Interest Coverage	-	-	-	-	-	-	-	-	-	-52.63x
FCF Conversion	0.89x	0.87x	1.02x	0.78x	-0.03x	5.81x	-3.99x	0.45x	0.76x	0.80x
Revenue Growth	-	-	-	-	-	-	-58.19%	-78.2%	-100%	-

Revenue by Segment

	2020	2021	2022
Manufacturing Revenue	18M	18M	4.01M
Manufacturing Revenue Growth	-	0.00%	-77.72%
Clinical Trial Service Revenue	25.98M	394K	-
Clinical Trial Service Revenue Growth	-	-98.48%	-
Product and Service, Other	22K	-	-
Product and Service, Other Growth	-	-	-

Frequently Asked Questions

Growth & Financials

XBiotech Inc. (XBIT) grew revenue by 0.0% over the past year. Growth has been modest.

XBiotech Inc. (XBIT) reported a net loss of $29.2M for fiscal year 2024.

Dividend & Returns

XBiotech Inc. (XBIT) has a return on equity (ROE) of -19.2%. Negative ROE indicates the company is unprofitable.

XBiotech Inc. (XBIT) had negative free cash flow of $23.8M in fiscal year 2024, likely due to heavy capital investments.